India's dual pricing pressures

Share this article:

India is struggling to keep its export drug business an enriching one. The Economic Times reports that international customers are aware of what the companies are charging in-country and now want similar prices for themselves. The Economic Times says companies are concerned that price parity would threaten their businesses, since India's price controls have driven prices down 60% for what the government considers essential medicines.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.